To Investigate the Role of Upstream High Dose Statin in STEMI

Completed · Phase 4 · Has a placebo group

Conditions studied: Acute Myocardial Infarction

In brief

This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.

Key facts

Study ID

NCT01050348

Run by

The Western Pennsylvania Hospital

People needed

120

Starts

2009-06-01

Expected to finish

2010-06-01

Last updated by the study team

2018-10-05

Who can join

Age: 25 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as greater than 1mm ST segment elevation on electrocardiogram.
• Elevated cardiac biomarkers (troponin-T > 0.03ng/ml, CKMB>5ng/mL, or ck>170 U/l).

You may not qualify if…

• Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non alcoholic steatohepatitis, hepatitis or any causes of liver failure.
• Renal failure with creatinine >3mg/dL
• Known history of liver or muscle disease such as rheumatologic myopathies, history of myositis, hepatitis, and hepatic cancer.
• Cardiovascular arrest and shock.

Where it is running

• Allegheny General Hospital — Pittsburgh, Pennsylvania, United States
• The Western Pennsylvania Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.